Key stakeholders

Value across every role in the staging pathway.

PathLogix is designed to be useful at the bench, defensible in the boardroom, and meaningful for the patient at the end of the report. Here's how value lands for each stakeholder - and where the real risks live.

Healthcare workers (PAs, pathologists, technicians, residents)

Value creation
  • Real-time decision support at the gross bench reduces cognitive load.
  • Standardized checklists make grossing more reproducible across PAs and sites.
  • Voice-driven dictation lets PAs keep hands on the specimen, not the keyboard.
Risks & concerns
  • Adoption risk if the system is perceived as replacing judgment instead of supporting it.
  • Training time required to learn the standardized workflow.

Healthcare administrators & CMOs

Value creation
  • Operational efficiency - protocols are followed consistently, reducing variability in care.
  • Better throughput under chronic staffing shortages.
  • Cleaner audit trails for accreditation and QA programs.
Risks & concerns
  • Integration cost into existing LIS / EHR workflows.
  • Change management across multiple labs and shifts.

Payers

Value creation
  • Fewer downstream complications from mis-staged cancers.
  • Potentially lower long-term care costs from earlier-stage-appropriate treatment.
Risks & concerns
  • Will require evidence the system reduces costs and improves outcomes.
  • Liability exposure if AI-influenced decisions lead to harm.

Patients

Value creation
  • Higher confidence that their tumor was sampled to standard.
  • Stage-appropriate treatment plans informed by precise macroscopic evaluation.
Risks & concerns
  • Transparency about how AI is used in their care pathway.